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Background: Acute exacerbations of chronic bronchitis (AECB) are defined as recurrent 
attacks of worsening bronchial inflammation that are marked by an increase in the volume of 
daily sputum produced, a change in color of the expectorated sputum, and worsening dyspnea. 
Farcosolvin® (Pharco Pharmaceuticals, Alexandria, Egypt) is a mixture of ambroxol (15 mg); 
theophylline (50 mg); and guaiphenesin (30 mg), per 5 mL syrup.
Objective: To test the clinical efficacy of Farcosolvin in the treatment of AECB in a random-
ized, single-blinded, controlled study design.
Patients and methods: One hundred patients with AECB were randomized to either Farco-
solvin or guaiphenesin treatment groups, in addition to the standard medical treatment for their 
cases. Baseline clinical symptomatolgy of breathlessness, cough, and sputum severity scoring 
were compared before and after 3 and 7 days of treatment in both groups and the differences 
compared between groups. Changes in perceived improvement were also compared between 
groups using the Clinical Global Impression of Improvement or Change Scale (CGIC).
Results: There were statistically significant improvements in breathlessness and cough scores in 
both groups (pretreatment versus posttreatment at day 3 and at day 7; P , 0.05). There were highly 
statistically significant differences between groups in improvement in   breathlessness and cough 
scores, after 3 and 7 days treatment, in favor of the Farcosolvin   treatment group (P , 0.001). Out 
of 50 patients, 48 (96%) in the Farcosolvin-treated group rated their   improvement on the CGIC 
scale as “much” and “very much” improved, while only 41 patients (82%) reported such a degree 
of improvement in the control group. The difference was statistically significant (P , 0.05).
Conclusion: We concluded from our study that Farcosolvin syrup might be safe and effective 
in improving symptoms in cases of acute exacerbation of chronic bronchitis.
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Introduction
Chronic bronchitis (CB) is a progressive disease characterized by chronic increase in 
the production of mucous. It is defined as the presence of a chronic cough with sputum 
production for at least three months, in each of two consecutive years, after other causes 
of cough, such as tuberculosis and lung cancer, have been eliminated.1,2
Acute exacerbations of chronic bronchitis (AECB) are defined as recurrent attacks 
of worsening bronchial inflammation that occur on average 1.5–3 times a year, and 
are superimposed on baseline CB.1 These exacerbations are marked by an increase in 
the volume of daily sputum produced; a change in color of the expectorated sputum 
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Ambroxol is a metabolite of bromhexine and is widely 
used as a mucolytic. It also induces the synthesis of surfactant 
in lung alveolar type II cells. By this mechanism, it decreases 
the work and effort of breathing and can improve respiratory 
symptoms. It has also been proved to have antioxidant and 
anti-inflammatory activities.3
It became evident that theophylline can exert anti-
  inflammatory and immunomodulating actions at lower plasma 
concentrations than those required for   bronchodilation.4 
Theophylline inhibits the production and release of 
  pro-inflammatory cytokines, including IL-1β, TNF-α, and 
IFN-γ. The production of the anti-inflammatory cytokine 
IL-10 is increased.
The guidelines of the Global Strategy for the   Diagnosis, 
Management, and Prevention of Chronic Obstructive Lung 
Disease (GOLD) currently recommend consideration of 
the addition of an oral or intravenous methylxanthine to 
  aerosolized bronchodilators, for management of severe 
exacerbations of chronic obstructive pulmonary disease 
(COPD).5
The effect of theophylline and ambroxol, when combined 
together, has been proved to give more than additive effects 
in improving the mucociliary clearance and increasing the 
release of respiratory surfactants.6,7
Guaiphenesin is a commonly used ‘over-the-counter’ drug 
for productive cough. It is reported to increase the   volume and 
reduce the viscosity of tenacious sputum. An US Food and 
Drug Administration (FDA) review of preparations   available 
‘  over-the-counter’ concluded that guaiphenesin was an effec-
tive expectorant.8
Farcosolvin® (Pharco Pharmaceuticals, Alexandria, 
Egypt) is a cough mixture of ambroxol (15 mg); theophylline 
(50 mg); guaiphenesin (30 mg), per 5 mL syrup. The purpose 
of this study is to test the clinical efficacy of Farcosolvin in 
the treatment of acute exacerbation of chronic bronchitis.
Methods
study design
A pragmatic, randomized, single-blinded, comparative study, 
designed to determine the efficacy of Farcosolvin syrup in 
reducing clinical symptom scores under conditions that 
reflect the usual medical care for AECB (defined as worsening 
of the baseline symptoms [cough, sputum, and breathless-
ness] of CB), was conducted.
Patients
To detect a difference in the mean severity of cough and 
expectoration score between the two treatment groups of 
4 points with a standard deviation (SD) of 5; a P value , 0.05; 
and an approximate power of 90%, we calculated the minimal 
needed sample size to be 68 patients. One hundred eligible 
patients were included in the study analysis according to the 
following criteria defined below.
Inclusion criteria
Patients were eligible for inclusion in the study if they were 
a male or female aged $45 years, with a history of smoking 
and a physician’s diagnosis of AECB. The diagnosis of CB 
was based on the history of cough and expectoration on most 
days during a period of at least three consecutive months 
for two consecutive years.1 AECB was classified as type I 
according to Anthonisen et al 9 when it met all three of the 
following criteria: increases in amount of sputum; purulence 
of sputum; and increasing dyspnea. AECB was classified as 
type II if it met two of the above three criteria and type III if 
it met only one criterion.9
exclusion criteria
Patients were excluded if they had any of the following 
conditions: heart failure or multiple organ dysfunctions: 
bronchiectasis; bronchial carcinoma; interstitial lung disease; 
pneumonia; inability to comply with the study procedures 
because of dementia; or if they had any other medical 
  problems that in the opinion of the investigator would inter-
fere with the conduct of study.
Protocol
The study was conducted at Mabarah Hospital and Green 
Clinics and was approved by the Ethics Committee and all 
participants provided written informed consent. All con-
secutive patients presenting to both centers who met the 
eligibility criteria between November 2005 and October 
2006 were allocated sequential numbers as they entered 
the study.
Patients were randomized into an experimental group, 
who were treated with Farcosolvin (5 mL syrup three times 
daily); and a control group, who were treated with a generic 
guaiphenesin syrup (100 mg per 5 mL three times daily). 
A block randomization technique was used to ensure that 
equal numbers were allocated to each group. Treatment was 
continued for 7 days or until clinical remission, whichever 
occurred first. In addition to Farcosolvin or guaiphenesin, all 
patients received standard treatment for their exacerbation as 
specified by their condition and the guidelines. This was anti-
biotic (ciprofloxacin 500 mg, twice daily, for 7 days); inhaled 
or nebulized bronchodilators in the form of   salbutamol International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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(two inhaler puffs or 5 mg in 2 mL saline nebulized); and/
or ipratropium 0.5 mg as needed, or up to four times daily. 
Mucolytics, theophylline and expectorants were not permitted 
during the trial, except as in the protocol.
Breathlessness was measured on a 7-point Likert scale 
(Appendix1). Severity of cough and sputum clearance was 
measured using the Modified Questionnaire for Ease of 
Cough and Sputum Clearance.10 At the end of one week 
treatment, all patients were asked to grade their impres-
sion of improvement or change in their condition using 
the Clinical Global Impression of Improvement or Change 
Scale (CGIC),11 which is a 7-point rated scale where 0 = not 
assessed; 1 = very much improved; 2 = much improved; 
3 = minimally improved; 4 =  no change; 5 = minimally 
worsened; 6 = much worsened; and 7 = very much worsened. 
Finally, all subjects were interrogated about any possible 
adverse effects.
statistical analysis
The two treatment groups were compared at baseline and at 
3 and 7 days, using tests for nonparametric data (Friedman, 
Kruskal–Wallis and Fisher’s exact tests). All tests were two-
tailed and a 5% significance level was maintained throughout 
these analyses. The analyses were carried out using SPSS 
software (Version 12; SPSS Inc. Chicago, IL, USA).
Results
The analysis included 100 patients with AECB grouped into 
two equal sized groups: an experimental group (50 patients), 
who were treated with Farcosolvin 5 ml syrup three times 
daily; and a control group (the remaining 50), who were 
given guaiphenesin syrup 3 times daily.
The two groups were almost matched at baseline in 
terms of age, smoking history, lung function, oxygen satura-
tion, severity of cough, and breathlessness (Table 1). Also, 
there was no significant difference between both groups 
for the concurrent medications they received during the 
study. All patients needed to be treated with antibiotic and 
bronchodilators were given on an as-needed basis, except 
for four patients in the Farcosolvin group and 6 in the 
Guaiphenesin control group who required regular inhaler 
use. One patient needed to be given a budesonide dry pow-
der inhaler at doses of 200 µg twice daily at day 3 due to 
worsening dyspnea.
The effects of treatment on breathlessness scores and 
cough scores were analyzed by nonparametric statistical 
methods as the distribution was found by Kolmogorov 
Smirnov to be not normal (P , 0.001).
There was a statistically significant improvement of 
breathlessness and cough scoring in both groups when 
compared before and after treatment at day 3 and at day 
7 (Tables 2 and 3), using a nonparametric related samples 
Friedman test (P , 0.05).
There was a highly statistically significant difference in 
improvement in breathlessness score, as well as cough score, 
in favor of Farcosolvin treatment when the two groups were 
compared using an independent samples Kruskal Wallis test 
(Tables 4 and 5).
Out of 50 patients, 48 (96%) in the Farcosolvin treated 
group rated their improvement on the CGIC scale as “much” 
and “very much” improved, while only 41 patients (82%) 
reported the same degree of improvement in the control group. 
The difference was statistically significant (P , 0.05).
Seven subjects reported adverse events in each group, 
including nausea and heartburn. Five of the subjects treated 
with Farcosolvin reported nausea compared with four of the 
subjects treated with guaiphenesin. There were no serious 
adverse events.
Discussion
To our knowledge, this is the first study to address the effects 
of a mixture of theophylline, ambroxol and guaiphenesin in 
relation to clinical manifestations and severity of symptoms 
of AECB.
This study showed significant improvement in breathless-
ness and severity of cough scores in patients treated with the 
Farcosolvin mixture than those treated with   guaiphenesin 
alone. Both ambroxol and theophylline have been   extensively 
studied in the treatment of CB. Ambroxol has been tested in 
many large multicenter, randomized, double blind controlled 
studies in cases of CB. The results confirm the previously 
seen improvement in symptomatology and the significant 
reduction in number and severity of exacerbations in groups 
Table 1 Baseline data for each group
Farcosolvin Guaiphenesin
gender: male/female 33/17 35/15
Age (years ± sD) 62.4 ± 6.7 61.7 ± 7.2
Breathlessness score (mean ± sD) 4.2 ± 1.0 4.0 ± 0.9
Breathlessness score (median) 4 4
Cough score (mean ± sD) 16.0 ± 1.8 15.8 ± 1.7
Cough score (median) 16 16
AECB classification frequency 
(Type I/I/III)
44/6/0 42/8/0
FeV1 (% of predicted ± sD) 66 ± 11 68 ± 12
O2 saturation (mean ± sD) 90.1 ± 4.2 90.3 ± 3.6
Abbreviations: AeCB, acute exacerbations of chronic bronchitis; FeV1, forced 
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treated with ambroxol versus placebo.12–14 In an open, long-
term multicenter study including 5635 patients, ambroxol 
was effective and well-tolerated for the prophylaxis of 
exacerbations of chronic bronchitis.2
Positive effects have been seen with the use of ambroxol 
in patients with early hypersecretory CB, including improve-
ment in coughing; dyspnea; color and consistency of   sputum; 
and ease of expectoration, when compared to a control 
(P , 0.05).13
Theophylline has also been proven effective in cases 
of CB and COPD.4 The accumulated evidence has led 
theophylline to be recommended as a treatment in addition 
to aerosolised bronchodilators for severe exacerbations of 
COPD, in the GOLD guidelines.5
The combination of theophylline plus ambroxol has been 
proven to give more than additive effects in mucociliary clear-
ance and increasing the release of respiratory surfactants.6,7 This 
was the basis of our study for the efficacy of the triple mixture 
of a theophylline, ambroxol, plus an expectorant, in cases with 
AECB, when sputum amount, content and viscosity changes 
added to compromised mucociliary clearance and surfactant 
release are among the factors leading to worsening of symptoms 
and general condition of patients. Our results, to some extent, 
can support our assumption that this mixture can be helpful in 
such patients through working against these factors.
Conclusion
We concluded from our study that Farcosolvin syrup might 
be safe and effective in improving symptoms in cases 
of AECB.
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Appendix 1 7-point Likert scale for breathlessness
7 extremely short of breath
6 Very short of breath
5 Quite a bit short of breath
4 Moderate shortness of breath
3 some shortness of breath
2 A little shortness of breath
1 not at all short of breath
Appendix 2 Modified questionnaire for ease of cough and sputum clearance (25-point scale)
Cough episodes: frequency
How frequently are you coughing today?
  1. none: unaware of coughing
  2. rare: cough now and then
  3. occasional: less than hourly
  4. frequent: one or more times an hour
  5. almost constant: never free of cough or feeling free of the need to cough
How frequently were you coughing last night?
  1. none: unaware of coughing
  2. rare: cough in the morning but I wasn’t woken from sleep
  3. occasional: woke a few times but I fell back asleep right away
  4. frequent: woken many times through the night with fits of coughing
  5. almost constant: up all night-long with coughing
Cough episodes: severity on arising and throughout the day
How severe were your cough episodes on a typical day during the past week?
  1. none: unaware of coughing
  2. mild: didn’t interfere with usual morning or daily activity
  3. moderate: must stop activity during coughing episodes
  4. marked: must stop activity during – and for a brief period after – coughing episodes
  5. severe: stops all activity for some time and is exhausting; can be accompanied by dizziness, headache, or pain
Ease of bringing up sputum during the day
How easy is it to cough up sputum when you cough today?
  1. none: unaware of coughing at all
  2. easy: sputum comes up without difficulty after only one or two coughs
  3. somewhat difficult: most of the sputum comes up but only after several hard coughs
  4. very difficult: some sputum comes up after hard coughing but there is the feeling that most is still sticking down there
  5. impossible: there is sputum down there but no matter how hard the coughing nothing comes up
Chest discomfort: tightness and/or congestion on arising and throughout the day
How much chest tightness or discomfort do you have today?
  1. none: unaware of any discomfort
  2. mild: noticeable now and then but is not bothersome and passes quickly; doesn’t limit activity
  3. moderate: noticeable during light activity, such as walking one block, or up one flight of stairs
  4. marked: noticeable while washing or dressing in the morning
  5. severe: almost constant and limits all activity; present even while resting
Appendices